GSK Out Licenses its Tuberculosis Vaccine (M72/AS01E ) to Bill & Melinda Gates Medical Research Institute
Shots:
- GSK has licensed its M72/AS01E to the Gates MRI for further development and potential use of vaccine therapy in low-income countries with high TB burdens
- Under the agreement- the GATES MRI will lead the development program and will be responsible to sponsor future clinical studies while GSK will provide the AS01 adjuvant for the development program
- GSK’s M72/AS01E consist of M72 recombinant fusion protein- derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A)- combined with the adjuvant system AS01
Click here to read full press release/ article
Ref: GSK | Image: GSK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
